Transcutaneous Auricular Vagus Nerve Stimulation as Adjuvant Treatment for Sepsis Patients
Key facts
- Who runs it
- Third Military Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 27 Feb 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- taVNS
- sham-taVNS
- Record updated
- 4 July 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Age 18-80
- Sepsis was diagnosed per the Sepsis-3 criteria (SCCM/ESICM 2016) as infection with SOFA score ≥ 2
- ICU admission within 7 days after sepsis onset
- Informed consent was obtained from patients/guardians
Who cannot take part
- taVNS contraindications: existing pacemakers, cochlear implants, or other active implantable electronic medical devices
- severe underlying pulmonary diseases including interstitial lung disease, -
- diffuse alveolar hemorrhage, severe asthma, or lung cancer
- dermatologic or infectious disorders affecting the auricular region
- inability to remain motionless during treatment (e.g., due to epilepsy or Parkinson's disease)
- severe ARDS defined by PaO₂/FiO₂ ≤100 mmHg with PEEP ≥5 cm H₂O
- HR>120 per minute
- epinephrine or norepinephrine >1ug/kg/min
- pregnancy or lactation
- participation in other clinical trials
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sepsis
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goals of this randomized clinical trial are to investigate the effects of transcutaneous auricular vagus nerve stimulation (taVNS) combined with standard intensive care on systemic organ function in septic patients, and exploring its potential mechanisms for improving overall outcomes in sepsis.The main question it aims to answer is whether taVNS can reduce the severity of sepsis patients by ameliorating systemic inflammation.Participants will receive standard intensive care treatment and be randomized to receive the taVNS or sham taVNS as adjuvant treatment twice a day for 7 consecutive days. Several evaluations will be done before and after the intervention.
The 2 groups in the trial
- taVNS groupTreatment being tested
transcutaneous auricular vagus nerve stimulation twice a day for 7 consecutive days.
Treatment: taVNS
- sham-taVNS groupSham treatment, for comparison
sham transcutaneous auricular vagus nerve stimulation twice a day for 7 consecutive days.
Treatment: sham-taVNS
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Exploratory Study on Transcutaneous Auricular Vagus Nerve Stimulation as Adjuvant Treatment for Sepsis Patients
- Criteria questions
- Built from NCT07051694, who can take part
- Record updated
- 4 July 2025